These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 27731807)
1. Beneficial anti-Parkinson effects of camel milk in Chlorpromazineinduced animal model: Behavioural and histopathological study. Khatoon H; Najam R; Mirza T; Sikandar B Pak J Pharm Sci; 2016 Sep; 29(5):1525-1529. PubMed ID: 27731807 [TBL] [Abstract][Full Text] [Related]
2. Effect of M. chamomilla L. tea on chlorpromazine induced catalepsy: A neuroprotective study. Khan SS; Ikram R; Naeem S; Khatoon H; Anser H; Sikander B Pak J Pharm Sci; 2020 Sep; 33(5):1945-1953. PubMed ID: 33824100 [TBL] [Abstract][Full Text] [Related]
3. Anticataleptic activity of Zamzam water in chlorpromazine induced animal model of Parkinson disease. Riaz B; Ikram R; Sikandar B Pak J Pharm Sci; 2018 Mar; 31(2):393-397. PubMed ID: 29618426 [TBL] [Abstract][Full Text] [Related]
4. Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats. Naeem S; Najam R; Khan SS; Mirza T; Sikandar B Metab Brain Dis; 2019 Aug; 34(4):1191-1199. PubMed ID: 31055785 [TBL] [Abstract][Full Text] [Related]
5. Neuroprotective potential of Beta vulgaris L. in Parkinson's disease. Nade VS; Kawale LA; Zambre SS; Kapure AB Indian J Pharmacol; 2015; 47(4):403-8. PubMed ID: 26288473 [TBL] [Abstract][Full Text] [Related]
6. Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson's disease rat model. Sharma N; Khurana N; Muthuraman A; Utreja P Eur J Pharmacol; 2021 Jul; 903():174112. PubMed ID: 33901458 [TBL] [Abstract][Full Text] [Related]
7. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221 [TBL] [Abstract][Full Text] [Related]
8. Activation of mitochondrial ATP-sensitive potassium channels improves rotenone-related motor and neurochemical alterations in rats. Yang Y; Liu X; Long Y; Wang F; Ding JH; Liu SY; Sun YH; Yao HH; Wang H; Wu J; Hu G Int J Neuropsychopharmacol; 2006 Feb; 9(1):51-61. PubMed ID: 15927086 [TBL] [Abstract][Full Text] [Related]
9. Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism. Abdin AA; Hamouda HE Neuropharmacology; 2008 Dec; 55(8):1340-6. PubMed ID: 18817789 [TBL] [Abstract][Full Text] [Related]
10. Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats. Muriel MP; Orieux G; Hirsch EC Mov Disord; 2002 Nov; 17(6):1174-9. PubMed ID: 12465054 [TBL] [Abstract][Full Text] [Related]
12. An Evaluation of the Effects of Pyridoxal Phosphate in Chlorpromazineinduced Parkinsonism using Mice. Olofinnade AT; Onaolapo TM; Oladimeji S; Fatoki AM; Balogun CI; Onaolapo AY; Onaolapo OJ Cent Nerv Syst Agents Med Chem; 2020; 20(1):13-25. PubMed ID: 31987026 [TBL] [Abstract][Full Text] [Related]
13. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity. Gluck MR; Santana LA; Granson H; Yahr MD J Neural Transm (Vienna); 2004 Jun; 111(6):713-24. PubMed ID: 15168218 [TBL] [Abstract][Full Text] [Related]
14. Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats. Lindner MD; Plone MA; Mullins TD; Winn SR; Chandonait SE; Stott JA; Blaney TJ; Sherman SS; Emerich DF Exp Neurol; 1997 May; 145(1):130-40. PubMed ID: 9184116 [TBL] [Abstract][Full Text] [Related]
15. NSAIDs ameliorate cognitive and motor impairment in a model of parkinsonism induced by chlorpromazine. Naeem S; Ikram R; Khan SS; Rao SS Pak J Pharm Sci; 2017 May; 30(3):801-808. PubMed ID: 28653925 [TBL] [Abstract][Full Text] [Related]
16. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161 [TBL] [Abstract][Full Text] [Related]
17. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222 [TBL] [Abstract][Full Text] [Related]
18. Drugs for Parkinson's disease. Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688 [TBL] [Abstract][Full Text] [Related]
19. 24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease. Ricciardi L; Bove F; Espay KJ; Lena F; Modugno N; Poon YY; Krikorian R; Espay AJ; Fasano A Mov Disord; 2016 Apr; 31(4):597-8. PubMed ID: 26946221 [No Abstract] [Full Text] [Related]
20. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by L-DOPA. Alam M; Mayerhofer A; Schmidt WJ Behav Brain Res; 2004 May; 151(1-2):117-24. PubMed ID: 15084427 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]